Biotech names continue to lead of our hot stocks list, after topping our list four out of five days last week.

The biotech sector was off to another strong start on Monday, as our hot stocks list was led by another biotech company.  Bluebird Bio (NASDAQ:BLUE) is a company which develops therapies for genetic diseases.  On Monday, BLUE shares skyrocketed 32.08 percent to $34.46 after the company reported positive results from its Phase I and II trials of LentiGlobin, which is intended for the treatment of beta-thalassemia major, a disorder which destroys red blood cells.

With all the recent excitement about India’s stock market and the anticipated impact of “Modinomics”, it was no surprise to see another big advance by India’s largest Internet portal, Rediff.com India (NASDAQ:REDF).  Rediff.com has seen its share price climb 27 percent since Narendra Modi took office as Prime Minister of India.  On June 11, REDF had a “golden cross” moment, when its 50-day moving average crossed above its 200-day moving average.  On Monday, REDF shares soared 22.71 percent to a one-year high of $3.62.  Monday’s trading volume of nearly 2.5 million shares was extraordinarily heavy, compared to Rediff’s average daily trading volume of approximately 333,000 shares.

Fusion-io (NYSEARCA:FIO) sells memory devices which are used for a variety of applications.  FIO shares jumped 22.41 percent to $11.36 on Monday, after SanDisk (NASDAQ:SNDK) made an offer to buy the company for $1.1 billion, or $11.25 per share.

Achillion Pharmaceuticals (NASDAQ:ACHN) is no stranger to our “hot stocks” list.  ACHN led our list on June 10, when it skyrocketed 83.29 percent after reaching the number two position on June 9, when it gained 47.57 percent.  Achillion benefitted from the June 9 buyout offer made by Merck (NYSEARCA:MRK) in its move to acquire Idenix Pharmaceuticals (NASDAQ:IDIX), a company with three drugs in clinical trials for the treatment of hepatitis C.   Achillion got a boost from the Idenix buyout because Achillion has a few hepatitis C drugs of its own in the approval pipeline.  Many investors are hoping to make a million with Achillion, should one of the other big pharma players become interested in a hepatitis C treatment.

On Monday, Achillion shares surged 20.87 percent to $7.82, after Maxim reiterated its “buy” rating on the stock and raised the price target from $6 to $22.

Bottom line:  After biotech stocks led our hot stocks list on four out of five days last week, Monday’s trading session brought biotech names to the number one and number four positions, suggesting that the biotech sector might have another strong week.